Field cancerization therapies for the management of actinic keratosis: an updated review
Saxenda is a GLP-1 receptor agonist used for weight management, not associated with increased UTI risk in clinical trials or post-marketing surveillance Unlike SGLT2 inhibitors which increase UTI risk through glucose excretion in urine, Saxenda works via appetite regulation through GLP-1 receptors Dehydration from Saxenda's gastrointestinal side effects (nausea, vomiting, diarrhoea) may indirectly increase UTI susceptibility by concentrating urine UTI symptoms include dysuria, urinary frequency, urgency, suprapubic pain, and cloudy or blood-stained urine requiring medical assessment NICE guidance recommends symptom-based diagnosis in women with nitrofurantoin as first-line treatment for uncomplicated lower UTIs Patients should maintain adequate hydration, practise good urogenital hygiene, and seek prompt medical advice for persistent urinary symptoms during Saxenda treatment Table of Contents Understanding Saxenda and Its Common Side Effects Saxenda (liraglutide 3.0 mg) is a prescription medicine licensed in the UK for weight management in adults with a BMI 30 kg/m, or 27 kg/m with weight-related health conditions
One of the key areas of interest is its potential in treating neuropathic pain and metabolic disorders
Once you have reviewed the post-treatment instructions, you may return home
Unlike tirzepatide that retains GCG function via counteracting with that of GLP-1 through activation of GIPR, peptide 20 is capable of activating GCGR directly
doi: 10.3389/fphar.2017.00313 [DOI] [PMC free article] [PubMed] [Google Scholar] 73
